Lantern Pharma says Phase 2 HARMONIC trial shows LP-300 lifts median PFS to 8.9 months in EGFR L858R lung cancer patients treated up to six cycles

Lantern Pharma, Inc.

Lantern Pharma, Inc.

LTRN

0.00
  • Lantern Pharma released updated Phase 2 HARMONIC trial results, already being used for partnering and clinical discussions during ASCO 2026.
  • Data reinforced a pattern of longer treatment translating into better disease control in EGFR L858R-mutant lung cancer following prior targeted therapy.
  • Responses appeared durable in some patients, with tumor shrinkage seen in a majority of those evaluable in the L858R subgroup.
  • A protocol change cleared by the FDA extends LP-300 dosing to eight cycles, reflecting confidence in sustained tolerability.
  • Safety remained consistent with standard chemotherapy, supporting longer use in a heavily pretreated population.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606020813BIZWIRE_USPR_____20260602_BW549826) on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.